Retrospective Analysis of Patients with Esophageal Cancer Treated with Radiotherapy and/or Chemoradiotherapy

Aims and background Esophageal cancer consists of 5% of all cancers. In Eastern Anatolia region of Turkey, the rate was found to be 16%. The primary aim of the study was to evaluate effect of the localization and histologic type of tumor, stage of cancer and treatment modality, patient's sex, a...

Full description

Saved in:
Bibliographic Details
Published in:Tumori 2012-07, Vol.98 (4), p.445-450
Main Authors: Kandaz, Mustafa, Ertekin, Mustafa Vecdi, Bilici, Mehmet
Format: Article
Language:English
Subjects:
Adenocarcinoma - therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma - therapy
Carcinoma, Squamous Cell - therapy
Chemoradiotherapy
Chemotherapy, Adjuvant
Dose-Response Relationship, Radiation
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - etiology
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophageal Neoplasms - radiotherapy
Esophageal Neoplasms - therapy
Feeding Behavior
Female
Humans
Kaplan-Meier Estimate
Karnofsky Performance Status
Male
Middle Aged
Neoplasm Staging
Radiotherapy Dosage
Radiotherapy, Adjuvant
Retrospective Studies
Risk Factors
Smoking - adverse effects
Turkey - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims and background Esophageal cancer consists of 5% of all cancers. In Eastern Anatolia region of Turkey, the rate was found to be 16%. The primary aim of the study was to evaluate effect of the localization and histologic type of tumor, stage of cancer and treatment modality, patient's sex, age and smoking status, Karnofsky performance score, and family history on survival. Methods and study design A total of 135 patients with locally advanced esophagus cancer were enrolled into the study. The factors (sex, age, Karnofsky performance status, localization, histology, stage of the disease, treatment modality) on survival were evaluated. Results After the end of treatment, overall survival was 20 months, median survival period was 13 months. The survival rates at 1, 3 and 5 years were 51.3%, 20.1% and 13.4%, respectively. Conclusions For patients with esophageal cancer, age, Karnofsky performance score, stage, treatment modality applied, chemotherapy protocol, number of cures and general survival rate were found to be the prognostic factors related to survival (P
ISSN:0300-8916
2038-2529
DOI:10.1177/030089161209800408